Alkem Laboratories FY26 Annual Earnings Summary

Potential US tariffs on pharmaceutical imports could impact margins; management called it 'hypothetical' and declined to provide specific mitigation strategy.

Sacubitril launch faces competitive pricing pressure; price erosion could impact US revenue growth in subsequent quarters.

US entry for denosumab is subject to ongoing litigation with Amgen, which could delay launch beyond FY26.

US business faces 3-4% YoY price erosion, which could offset volume gains and pressure margins.

CDMO and medtech businesses will incur significant opex (₹50-60 crore per quarter) in H2 FY26, delaying margin expansion.

GST revision will reduce benefits from Sikkim facility, causing a ₹50-60 crore impact in H2, pressuring margins.

CDMO plant opex of ₹50 cr/quarter with only ₹20 cr revenue initially; breakeven expected in 12-18 months, but delays could weigh on profitability.

The government's MIP on penicillin derivatives could impact gross margins by 50-100 bps, though management expects to mitigate via pricing actions in trade generic business.

Occlutech operates in a different segment (medtech) with complex regulatory and manufacturing requirements; integration and scaling may face challenges.

Employee costs rose 15% YoY due to higher incentives; management expects lower growth in subsequent quarters, but volatility remains.

Government may impose minimum import price on Penicillin G; management declined to comment, citing speculation, but it could increase costs.

Trade generic business has been flat to low single-digit growth due to competitive pressures and conscious margin protection, potentially dragging overall domestic growth.